A 62176

Known as: A-62176 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
In the late 1980s, reports emerged describing experimental antibacterial quinolones having significant potency against eukaryotic… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2012
2012
HER2 overexpression is observed in ∼6-35% of all gastric cancers, while co-amplification of topoisomerase IIα occurs in ∼32-90… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2008
2008
Fluoroquinolones, represented by ciproxacin and norfloxacin, are well-known clinical antimicrobial agents, and their phenyl ring… (More)
Is this relevant?
2006
2006
We have synthesized several new quinophenoxazine analogues and tested their cytotoxicity activities. The results showed that the… (More)
Is this relevant?
2003
2003
Topoisomerase II, an enzyme that catalyzes changes in the topology of DNA, plays several key roles in DNA metabolism and… (More)
Is this relevant?
2002
2002
Acknowledgements First and foremost I would like to sincerely thank my supervisor Dr. Laurence H. Hurley for his inspiration and… (More)
  • figure 1.1
  • figure 1.2
  • figure 2.1
  • figure 2.2
  • figure 2.3
Is this relevant?
1999
1999
Quinobenzoxazine A-62176, developed from the antibacterial fluoroquinolones, is active in vitro and in vivo against murine and… (More)
Is this relevant?
1999
1999
The quinobenzoxazine compounds, derived from antibacterial quinolones, is active in vitro and in vivo against murine and human… (More)
Is this relevant?
1995
1995
The quinobenzoxazine compounds A-62176 and A-85226 belong to a novel class of antineoplastic agents that are catalytic inhibitors… (More)
Is this relevant?
1994
1994
The antineoplastic quinobenoxazines A-62176 and A-74932 were shown to be potent inhibitors of mammalian DNA topoisomerase II in… (More)
Is this relevant?